Neuronascent (NNI) discovers and develops therapies for depression, Down syndrome, post-traumatic stress disorder, Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Our lead candidate for each indication have shown great promise in several cell culture and disease models and show no sign of toxicity or other harmful effects. These, small-molecule, therapeutic candidates all promote new neurons from the brain’s own neuronal stem/progenitor cell populations. Preclinical studies of these candidates are currently under way, in-house and through contract laboratories, to complete the requirements for testing in humans.

Each NNI therapeutic candidate is uniquely optimized to increase neuron numbers in the brain, to improve critical function and to diminish loss of neurons due to disease progression. This ensures that each therapy is optimal for the indication.

NEWS & EVENTS

Oct 20, 2011 - Neuronascent Issued US Patent for Neurogenesis, Therapeutic Candidates - Read

June 27 - 30, 2011 - Dr. Kelleher-Andersson, the President and CSO of Neuronascent, is planning to attend the BIO meeting in Washington D.C. This BIO International meeting “is the largest global event for the biotechnology industry”. It also “offers key networking and partnering opportunities” for small biotech companies like Neuronascent.

Dec 14, 2010 - Judith Kelleher-Andersson, Ph.D., the founder and CSO of Neuronascent was an invited speaker at CBI’s 4th Annual Alzheimer’s Disease Drug Discovery Summit. Read

More News